
Recent advancements in one-shot AI protein / antibody development by Chai, Nabla, AI Proteins, Generate, and a few others are accelerating the *main* theme in biotech: Value of building the molecule is going down. The value of novel targets, novel translational ideas, AND also the value of clinical execution is going UP Here's where the value graph is moving towards: The twin forces of AI and China are quickly driving down price of mlc dev across many modalities: For AI - mainly Ab right now, emerging for genetic medicines, small mlc, ADCs, cell therapy; For China - Abs, cell and gene therapy, small mlc, and soon genetic medicines Having a "best in class" mlc is no longer enough - many tech platforms will soon offer you a mlc priced on metered compute (getting cheaper) and China CROs / biotechs will continue to eat the world with (over)capacity (continued involution). To make a valuable drug, you must differentiate on either: a) Novel translational ideas. Novel targets, novel mechanisms, but not just that - connecting targets with diseases; novel application of certain targets in new disease settings, new intuition on which patient pops have widest therapeutic index for a drug, etc OR b) Clinical execution. Determining the appropriate endpoints in a trial. Recruiting the right patients. Appropriate relationships with the right PIs / clinical sites. Ability to finance registrational studies in US markets ($10s to 100s of Ms) Either be a translational target discovery engine / tech platform that unlocks new modalities (which unlocks new translational hypotheses) OR get a team of grizzled clin dev / CMO vets and go raise $X00M+ to validate a clinical hypothesis Living in the middle (ie being "full stack") is dangerous work (at least for a startup)
**A grand unified theory on what will happen in biotech in the next 10-20 years** the two major forces reshaping industrial biotech in the next decade are: 1. China 2. AI - and they're critically linked how? China's low R&D cost basis democratizes execution by providing infrastructure to more drug developers (similar to how AWS helped cloud apps explode in 2010s) AI makes scientific information much more freely available; agents & lab automation increase R&D productivity as well as throughput, further deflating development costs What happens when many more translational ideas can be tried much more cheaply? Value starts accruing in the best ideas to try ie the value shifts earlier in the value chain if the cost of everything from preclinical R&D to clinical trials are dropping significantly due to combo of AI and China, the disparity between clinical stage vs early pipeline assets shrinks dramatically from the current order of magnitude difference The premium on true creativity, novel scientific insight, fundamentally new biology will 100x In a few years the top-of-industry drug hunters / translational biologists will command a hefty premium (maybe not $100m a year like current top AI scientists but ... maybe??) Even more provocatively, foundational models in translational biology that surface / accelerate novel biological hypotheses will suddenly capture outsized value When will a translational foundational model be worth more than a top 10 pharma co? sounds crazy... but like everything else --> slowly, then all at once












